secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARTIVION, INC. (AORT)
CIK:        0000784199
Form:       8-K
Filed at:   2023-02-16T23:59:59+00:00
Accession:  0000784199-23-000014
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Artivion Q4 GAAP EPS $0.05 vs ($0.51) loss; 2023 revenue outlook $331M-$343M
----------------------------------------------------------------------------

- Q4 revenue $79.4M, flat GAAP, +5% constant currency; On-X +11% CC, aortic stent grafts +16% CC.
- GAAP net income $2.2M ($0.05 EPS) vs net loss $20.1M ($0.51); non-GAAP $4.2M ($0.10).
- FY2022 revenue $313.8M (+5% GAAP, +9% CC); net loss $19.2M ($0.48) vs $14.8M ($0.38) in 2021.
- Received CE mark for BioGlue under EU MDR in Q4 2022.
- 2023 guidance: CC revenue growth 8-12%, revenue $331M-$343M, adjusted EBITDA >$50M (+20%).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/784199/000078419923000014/0000784199-23-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/784199/000078419923000014/aort-20230216.htm
  HTML page:      https://secwatch.observer/filing/0000784199-23-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer